Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Syh2070

Phase 2

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Mixed HyperlipidemiaRecruiting

Mixed HyperlipidemiaPhase 2

Recruiting

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Mixed Hyperlipidemia

NCT07695597

Clinical

Trials by Indication[1]

Mixed Hyperlipidemia1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Mixed Hyperlipidemia

Recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 2·NCT07695597·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Syh2070. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Syh2070. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Related News